CA2484600A1 - Therapeutic use of selective pde10 inhibitors - Google Patents

Therapeutic use of selective pde10 inhibitors Download PDF

Info

Publication number
CA2484600A1
CA2484600A1 CA002484600A CA2484600A CA2484600A1 CA 2484600 A1 CA2484600 A1 CA 2484600A1 CA 002484600 A CA002484600 A CA 002484600A CA 2484600 A CA2484600 A CA 2484600A CA 2484600 A1 CA2484600 A1 CA 2484600A1
Authority
CA
Canada
Prior art keywords
pde10
disorder
mammal
selective
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002484600A
Other languages
English (en)
French (fr)
Inventor
Lorraine Ann Lebel
Frank Samuel Menniti
Christopher Joseph Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/139,183 external-priority patent/US20030018047A1/en
Application filed by Individual filed Critical Individual
Publication of CA2484600A1 publication Critical patent/CA2484600A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
CA002484600A 2002-05-03 2003-04-22 Therapeutic use of selective pde10 inhibitors Abandoned CA2484600A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/139,183 2002-05-03
US10/139,183 US20030018047A1 (en) 2001-04-20 2002-05-03 Therapeutic use of selective PDE10 inhibitors
US10/177,018 2002-06-20
US10/177,018 US20030032579A1 (en) 2001-04-20 2002-06-20 Therapeutic use of selective PDE10 inhibitors
PCT/IB2003/001684 WO2003093499A2 (en) 2002-05-03 2003-04-22 Therapeutic use of selective pde10 inhibitors

Publications (1)

Publication Number Publication Date
CA2484600A1 true CA2484600A1 (en) 2003-11-13

Family

ID=29406263

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002484600A Abandoned CA2484600A1 (en) 2002-05-03 2003-04-22 Therapeutic use of selective pde10 inhibitors

Country Status (16)

Country Link
US (2) US20030032579A1 (https=)
EP (1) EP1504118A2 (https=)
JP (1) JP2005524402A (https=)
KR (1) KR20040106455A (https=)
CN (1) CN1668761A (https=)
AU (1) AU2003222395A1 (https=)
BR (1) BR0309746A (https=)
CA (1) CA2484600A1 (https=)
HR (1) HRP20041029A2 (https=)
IL (1) IL164778A0 (https=)
MX (1) MXPA04010777A (https=)
NO (1) NO20044470L (https=)
PL (1) PL373943A1 (https=)
RU (1) RU2303259C2 (https=)
TW (1) TWI269812B (https=)
WO (1) WO2003093499A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050945A (sr) * 2003-06-30 2008-06-05 Altana Pharma Ag., Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera
US20070105840A1 (en) * 2003-06-30 2007-05-10 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
EP1723134A2 (en) * 2004-02-18 2006-11-22 Pfizer Products Incorporated Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
EP1755611A1 (en) * 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
KR100896380B1 (ko) * 2005-01-07 2009-05-08 화이자 프로덕츠 인코포레이티드 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도
AU2006218054A1 (en) * 2005-01-12 2006-08-31 Nycomed Gmbh Novel pyrrolodihydroisoquinolines as PDE10 inhibitors
US20090176829A1 (en) 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
CA2661850A1 (en) * 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
US20090318385A1 (en) * 2006-09-06 2009-12-24 Yasushi Kohno Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP5580192B2 (ja) * 2007-03-27 2014-08-27 オメロス コーポレーション 運動障害の処置のためのｐｄｅ７インヒビターの使用
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
KR20100110804A (ko) * 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
EP2227472A1 (en) * 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
EP2318410A2 (en) * 2008-07-09 2011-05-11 Envivo Pharmaceuticals, Inc. New small-molecule pde-10 inhibitors
AU2009279756B2 (en) 2008-08-05 2015-01-29 Omeros Corporation PDE10 inhibitors and related compositions and methods
TW201018682A (en) * 2008-09-25 2010-05-16 Kyorin Seiyaku Kk Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
WO2010041711A1 (ja) * 2008-10-09 2010-04-15 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
CN105125547A (zh) 2009-05-07 2015-12-09 费瑞姆医药有限公司 苯氧基甲基杂环化合物
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
TW201111383A (en) 2009-05-29 2011-04-01 Wyeth Llc Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10
WO2010144416A1 (en) * 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
CA2765750A1 (en) 2009-06-19 2010-12-23 H. Lundbeck A/S Novel phenylimidazole derivative as pde10a enzyme inhibitor
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
KR101713453B1 (ko) * 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
CA2827724A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
SG11201402134VA (en) 2011-11-09 2014-06-27 Abbvie Deutschland Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TWI570124B (zh) 2011-12-21 2017-02-11 Ｈ 朗德貝克公司 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物
US9138494B2 (en) 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014001314A1 (en) * 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
US9464085B2 (en) 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
WO2014041175A1 (en) 2012-09-17 2014-03-20 Abbott Gmbh & Co. Kg Novel inhibitor compounds of phosphodiesterase type 10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
NZ708593A (en) 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EP2970258B1 (en) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Novel inhibitor compounds of phosphodiesterase type 10a
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
FI3846788T3 (fi) * 2018-09-05 2025-12-17 Univ Amsterdam Pde11-estäjiä parkinsonin taudin hoitoon
CN110346004B (zh) * 2019-08-16 2020-08-21 杭州山科智能科技股份有限公司 一种双声道超声时差法的流量测量数据融合方法
CN116137811B (zh) * 2020-06-05 2026-01-09 诺埃玛制药公司 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途
US12544364B2 (en) 2020-06-05 2026-02-10 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
WO2022162193A1 (en) * 2021-01-28 2022-08-04 Noema Pharma Ag Methods for the treatment of childhood-onset fluency disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ194348A (en) * 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
NO941915L (no) * 1993-05-25 1994-11-28 Daiichi Seiyaku Co Madikament for nervebeskyttelse
US5487976A (en) * 1993-10-15 1996-01-30 Cornell Research Foundation, Inc. DNA encoding an insect gamma-aminobutyric acid (GABA) receptor subunit cells expressing it, and pesticide screening methods using such cells
US20040152106A1 (en) * 1999-10-07 2004-08-05 Robertson Harold A. Gene necessary for striatal function, uses thereof, and compounds for modulating same
ATE321147T1 (de) * 2001-07-31 2006-04-15 Pfizer Prod Inc Auf zellen gegründetes phosphodiesterase-10a- assay und sequenzen

Also Published As

Publication number Publication date
CN1668761A (zh) 2005-09-14
AU2003222395A1 (en) 2003-11-17
EP1504118A2 (en) 2005-02-09
TWI269812B (en) 2007-01-01
TW200307751A (en) 2003-12-16
MXPA04010777A (es) 2005-03-07
KR20040106455A (ko) 2004-12-17
RU2303259C2 (ru) 2007-07-20
PL373943A1 (en) 2005-09-19
IL164778A0 (en) 2005-12-18
BR0309746A (pt) 2007-03-27
JP2005524402A (ja) 2005-08-18
RU2004132198A (ru) 2005-04-20
NO20044470L (no) 2004-11-04
WO2003093499A2 (en) 2003-11-13
US20040162294A1 (en) 2004-08-19
US20030032579A1 (en) 2003-02-13
HRP20041029A2 (en) 2004-12-31
WO2003093499A3 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
US20040162294A1 (en) Therapeutic use of selective PDE10 inhibitors
EP1250923A2 (en) Use of selective PDE10 inhibitors for the treatment of central nervous system disorders
Xu et al. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders
Kehler et al. PDE10A inhibitors: novel therapeutic drugs for schizophrenia
Zhang et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme
Hutson et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo [3, 4-d] pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents
Shan et al. Characterization of a functional (pro) renin receptor in rat brain neurons
Verrier et al. The brain in vivo expresses the 2′, 3′‐cAMP‐adenosine pathway
Santos et al. Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5
P Kelly Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?
J. Titus et al. Phosphodiesterase inhibitors as therapeutics for traumatic brain injury
US20040162293A1 (en) Therapeutic use of selective PDE10 inhibitors
Wersinger et al. Comparative analyses of α-synuclein expression levels in rat brain tissues and transfected cells
L Snyder et al. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment
EP1666886A2 (en) Method of identifying selective PDE10 inhibitor compounds
ZA200407823B (en) Therapeutic use of selective PDE10 inhibitors
Siuciak et al. Treating neuropsychiatric disorders with PDE10A inhibitors
AU2007200574A1 (en) Therapeutic use of selective PDE10 inhibitors
HK1091746A (en) Therapeutic use of selective pde10 inhibitors
Charych et al. Molecular And Cellular Understanding of PDE10A: A Dual‐Substrate Phosphodiesterase with Therapeutic Potential to Modulate Basal Ganglia Function
US20040023312A1 (en) Method for diagnosing huntingtons disease and means of treating it
HK1077331A (en) Therapeutic use of selective pde10 inhibitors
Lusche et al. cGMP-phosphodiesterase antagonists inhibit Ca2+-influx in Dictyostelium discoideum and bovine cyclic-nucleotide-gated-channel
Sanz Differentiating Human iPSCs into Dopaminergic Neurons that Express Classical Biochemical Traits and Show Neuronal Transmission and Excitability
Zhang Neuropsychopharmacological Effects of Selective Inhibitors of Subtypes of Phosphodiesterase-4 in Mice

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued